Latest Articles
'Years being dismissed': Endometriosis patient campaigns for Jess's rule in Wales - ITVX
'Years being dismissed': Endometriosis patient campaigns for Jess's rule in Wales ITVX
Published: Feb. 27, 2026, 6:51 p.m.
How Endometriosis Patients Can Change The World: Cat Bohannon On Healt - Endometriosis Foundation of America
How Endometriosis Patients Can Change The World: Cat Bohannon On Healt Endometriosis Foundation of America
Published: Feb. 27, 2026, 4:54 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat
Published: Feb. 27, 2026, 4:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance
Published: Feb. 27, 2026, 4:47 p.m.
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval - TradingView
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval TradingView
Published: Feb. 27, 2026, 3:34 p.m.
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data TipRanks
Published: Feb. 27, 2026, 3:24 p.m.
Advancing support for endometriosis and menstrual wellbeing - GOV.UK
Advancing support for endometriosis and menstrual wellbeing GOV.UK
Published: Feb. 27, 2026, 3:11 p.m.
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion - TradingView
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion TradingView
Published: Feb. 27, 2026, 2:50 p.m.
13 Years After Diagnosis, I Still Feel Unprotected As An Endometriosis Sufferer - HuffPost UK
13 Years After Diagnosis, I Still Feel Unprotected As An Endometriosis Sufferer HuffPost UK
Published: Feb. 27, 2026, 2:48 p.m.
Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer - Stock Titan
Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer Stock Titan
Published: Feb. 27, 2026, 2 p.m.
Link copied to clipboard!